Therapeutic Response in the HAWK and HARRIER Trials Using Deep Learning in Retinal Fluid Volume and Compartment Analysis

AI Generated Summary*

Post-hoc analysis of the HAWK and HARRIER trials used deep learning to quantify intraretinal fluid, subretinal fluid and pigment epithelial detachment volumes on 41,840 OCT scans from 1817 treatment-naive eyes with neovascular age-related macular degeneration given brolucizumab or aflibercept. Intraretinal fluid fell by 92% and subretinal fluid by 74% after one injection; detachment volume dropped 68 to 79% during loading. Subretinal fluid resolution was greater with brolucizumab 6 mg than aflibercept in both trials (p<0.001), while intraretinal fluid clearance was similar. Higher post-loading fluid in every compartment was independently linked to vision loss during maintenance; high and low volume groups differed in mean acuity change by 3.4 letters for intraretinal, 1.7 for subretinal and 2.5 for detachment.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.